白蛋白紫杉醇、卡铂新辅助化疗与卡瑞利珠单抗免疫治疗联合手术治疗进展期食管癌的临床效果

Clinical Effect of Neoadjuvant Chemotherapy with Albumin-paclitaxel and Carboplatin Combined with Camrelizumab Immunotherapy in the Treatment of Advanced Esophageal Cancer

目的:探讨进展期食管癌患者采用白蛋白紫杉醇、卡铂新辅助化疗与卡瑞利珠单抗免疫治疗联合手术治疗的临床效果。方法:选取2019年1月—2023年4月汕头市潮阳区大峰医院收治的进展期食管癌患者41例为研究对象,根据不同的治疗方法分为对照组(20例,采用单纯手术治疗)和观察组(21例,在对照组基础上联合白蛋白紫杉醇、卡铂新辅助化疗与卡瑞利珠单抗免疫治疗)。比较两组临床疗效、癌症标志物水平及不良反应发生率。结果:观察组及临床疗效总有效率高于对照组,差异有统计学意义(P=0.032);治疗后,两组细胞角蛋白19片段、鳞状细胞癌抗原、糖类抗原19-9和癌胚抗原水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:进展期食管癌患者采用白蛋白紫杉醇、卡铂新辅助化疗与卡瑞利珠单抗免疫治疗联合手术治疗的效果较为显著,有利于降低其癌症标志物水平,且安全性良好。

Objective:To investigate the clinical effect of neoadjuvant chemotherapy with albumin-paclitaxel,carboplatin and Camrelizumab immunotherapy combined with surgery in patients with advanced esophageal cancer.Methods:A total of forty-one patients with advanced esophageal cancer admitted to Shantou Chaoyang District Dafeng Hospital from January 2019 to April 2023 were selected as the study objects.According to different treatment methods,they were divided into control group(20 cases,treated with surgery alone)and observation group(21 cases,combined with albumin paclitaxel,carboplatin neoadjuvant chemo-therapy and Camrelizumab immunotherapy).The clinical efficacy,the level of cancer markers and the incidence of adverse reac-tions were compared between the two groups.Results:The total effective rate of observation group and clinical efficacy was higher than that of control group,the difference was statistically significant(P=0.032);After treatment,the levels of cytokeratin 19 frag-ment,squamous cell carcinoma antigen,carbohydrate antigen 19-9 and carcinoembryonic antigen in 2 groups were lower than be-fore treatment,and the observation group was lower than the control group,the difference was statistically significant(P<0.05);There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combi-nation of neoadjuvant chemotherapy with albumin-paclitaxel,carboplatin and Camrelizumab immunotherapy for patients with ad-vanced esophageal cancer has a significant effect,which is conducive to reducing the level of cancer markers and has good safety.